Bal Pharma FY26 Results: Revenue Up, Profit Down, Dividend Recommended

Bal Pharma Ltd announced its audited financial results for the fiscal year ended March 31, 2026. Consolidated revenue grew to ₹311.66 crore, up from ₹303.08 crore in FY25. Despite the revenue increase, consolidated net profit saw a decline to ₹6.32 crore from ₹7.24 crore in the previous year.

Revenue Growth vs. Profit Decline

Bal Pharma's consolidated revenues increased by 2.7% to ₹311.66 crore for the fiscal year 2025-26. Standalone revenues also saw a similar rise of 2.7%, reaching ₹310.80 crore.

However, profitability faced pressure. Consolidated net profit fell by 12.7% to ₹6.32 crore. Standalone net profit also declined by 13.4% to ₹6.75 crore for FY26 compared to FY25.

Why This Matters for Investors

The results highlight a common challenge: growing sales while struggling to maintain profit margins. This could stem from increased operational costs or other factors impacting efficiency. The company's board aims to reward shareholders by recommending a dividend, while also signaling promoter commitment through the approval of warrants.

Performance in Context

In the previous fiscal year, FY25, Bal Pharma reported consolidated revenue of ₹303.08 crore and a consolidated net profit of ₹7.24 crore. The current year's performance shows a divergence between top-line growth and bottom-line results, indicating that increased sales did not translate into proportional profit gains.

Key Decisions and Approvals

The company's board has recommended a dividend of ₹1.20 per equity share (12%) for FY26, pending shareholder approval. In addition, 10,00,000 warrants are set to be issued to promoters on a preferential basis, subject to shareholder consent via postal ballot. The company also approved the grant of 5,00,000 stock options under its Employees Stock Option Plan (ESOP).

Potential Concerns

Declining profitability despite revenue growth is a key area for investor attention. Future financial periods will be watched for signs of improved cost management and margin expansion. Any delays in securing shareholder approval for the preferential issue of warrants could also be a factor to monitor.

Key Financial Metrics (FY25-26)

• FY26 Consolidated Revenue: ₹311.66 crore
• FY25 Consolidated Revenue: ₹303.08 crore
• FY26 Consolidated Net Profit: ₹6.32 crore
• FY25 Consolidated Net Profit: ₹7.24 crore
• Recommended Dividend: ₹1.20 per equity share

What to Watch Next

Investors will be keen to observe Bal Pharma's strategies for enhancing profitability in the upcoming fiscal year. The completion of the preferential warrant issue and the impact of the ESOP grants on employee motivation are also points of interest. Governance updates include the appointment of Mr. Shreepada ML as Company Secretary, effective May 27, 2026.